Neuphoria Therapeutics (NEUP) Registration filing summary

Company overview and business model

• Clinical-stage biopharmaceutical company focused on novel allosteric ion channel modulators for CNS disorders with high unmet need, including PTSD and SAD.

• Lead candidate BNC210 targets the α7 nicotinic acetylcholine receptor for PTSD and SAD; pipeline includes preclinical assets for other CNS conditions.

• Strategic partnership with Merck (MSD) for α7 receptor positive allosteric modulators in cognitive dysfunction.

• Redomiciling from Australia to Delaware, USA, via a Scheme of Arrangement, with share exchange ratios set for ordinary shares and ADSs.

Financial performance and metrics

• As of November 18, 2024, public float of ADSs was approximately $12.6 million, with 19,417,351 ADSs outstanding.

• In the past 12 months, 1,690,451 ADSs sold for gross proceeds of ~$2.19 million.

• Cash and cash equivalents as of September 30, 2024: $8.08 million actual, $9.82 million as adjusted for offering.

• Net tangible book value per ADS as of September 30, 2024: $0.15; post-offering (as adjusted): $0.21 per ADS.

Use of proceeds and capital allocation

• Net proceeds intended for pipeline development, working capital, and general corporate purposes, including potential acquisitions and strategic transactions.

• Management retains broad discretion over allocation of proceeds.